Discover more near‑term opportunities with better event intelligence.
Fundz combines its own real-time funding and M&A intelligence with executive moves, hiring shifts and other company changes, weighs each signal against your ideal customer profile, and delivers a ranked daily shortlist with the context and decision maker to contact. Now it answers in Claude too: ask for today’s leads, then write the note in the same window.
Trusted by
OracleSnowflakeCloudflareLinkedInGoogleSalesforce
★★★★★4.8/5 on G2· Since 2015
Jasper Therapeutics Appoints Interim Executives Following CFO Resignation
PUBLIC · JSPRSep 28, 2026
Position
Principal
Company
Jasper Therapeutics
Rick Ruiz
Redwood CityBiotechnologyHealth CareTherapeutics
Description
On September 28, 2026, Jasper Therapeutics appointed new interim officers following the resignation of Herb Cross. Jeet Mahal takes on the role of interim Principal Financial Officer, while Rick Ruiz steps in as interim Principal Accounting Officer. Matthew Ros has been appointed as the interim Corporate Secretary, effective immediately following Mr
Company Information
Company
Jasper Therapeutics
Location
Redwood City, California, United States
About
Our mission is to make safer and potentially curative therapy possible for more patients in need. We are bringing together a team of biotech veterans, leading academic institutions and a strong syndicate of healthcare-focused investors to achieve our vision of developing new therapies for diseases of mast and stem cells, safer and more effective conditioning for monogenetic diseases and new engineered stem cell therapies. Briquilimab (formerly JSP191) is a targeted anti c-Kit monoclonal antibody designed to deplete diseased mast and stem cells as well as enable safer and more effective curative hematopoietic stem cell transplants and stem cell gene therapies.
Fundz sees it the moment Jasper Therapeutics changes its leadership, hires an exec or expands, usually minutes after it happens, and tells you who to reach.